The pathway to secondary prevention of Alzheimer's disease: Timing, Selection, and Endpoint of Clinical Trials

Research output: ThesisResearch VU University Amsterdam, graduation VU University Amsterdam

Abstract

Alzheimer's disease (AD) is a continuum consisting of a preclinical stage that occurs decades before symptoms appear. As researchers make advances in investigating the continuum, the importance of developing drugs for secondary prevention is garnering increased discussion. For efficacious drug development for secondary prevention it is important to define what are the earliest biological stages of AD. The Alzheimer's Association Research Roundtable convened November 27 to 28, 2018 to focus on pre-clinical AD. This review will address the biological approach to defining pre-clinical AD, detection, identification of at-risk individuals, and lessons learned from trials such as A4 and TOMMORROW.

Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
  • Vrije Universiteit Amsterdam
Supervisors/Advisors
  • Scheltens, Philip, Supervisor
  • Visser, Pieter, Co-supervisor
  • Tijms, Betty, Co-supervisor
Award date13 Mar 2020
Edition1
DOIs
Publication statusPublished - 2020

Cite this